Gastric Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery), By End User (Ambulatory Surgery Centers, Hospitals and Specialty Clinics, Other), By Region & Competition, 2020-2030F

Market Overview

The Gastric Cancer Therapy market was valued at USD 3.98 Billion in 2024 and is expected to reach USD 5.70 Billion by 2030 with a CAGR of 6.12%. The Global Gastric Cancer Therapy Market revolves around the diagnosis, treatment, and management of gastric cancer, also known as stomach cancer. Gastric cancer is a malignant tumor that develops in the lining of the stomach. This market encompasses a range of therapeutic interventions, diagnostic tools, and supportive care options aimed at combating the disease at various stages. The market is characterized by a variety of treatment modalities, including surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and combination therapies. Surgery involves the removal of cancerous tissue and, in some cases, parts of the stomach. Chemotherapy and radiation therapy are used to shrink tumors and eliminate cancer cells. Targeted therapies focus on specific molecular targets, inhibiting tumor growth and spread.

Immunotherapies harness the immune system to target and destroy cancer cells. The market's growth is driven by factors such as the rising incidence of gastric cancer, particularly in certain regions with high prevalence, and increased awareness leading to early diagnosis. Advances in medical technology, the emergence of precision medicine, and ongoing research contribute to the development of more effective and personalized treatment approaches. Collaborations between pharmaceutical companies, research institutions, and healthcare providers enhance the availability of innovative therapies. However, challenges such as treatment resistance, high treatment costs, and limited access to advanced therapies in some regions influence market dynamics. Patient-centered care, supportive care options to manage treatment side effects, and the integration of biomarkers for early detection are also important considerations within the market. In conclusion, the Global Gastric Cancer Therapy Market addresses the critical need for effective diagnostics, treatment options, and supportive care measures for patients diagnosed with gastric cancer. Advances in medical science, increasing awareness, and collaborative efforts continue to shape the market's landscape, striving to improve patient outcomes and quality of life.

Key Market Drivers

Rising Incidence of Gastric Cancer

The rising incidence of gastric cancer is one of the most significant drivers of the global gastric cancer therapy market. In 2020, global statistics revealed approximately 1.1 million new cases of gastric cancer, leading to 770,000 related deaths. The incidence of the disease is notably higher in males, with rates roughly double those seen in females. Eastern Asia remains the region with the highest incidence rates for both genders, highlighting a significant regional disparity in the global gastric cancer burden. As the number of diagnosed cases continues to rise worldwide, the demand for effective treatments and therapeutic interventions grows correspondingly. This increase in incidence is fueled by various factors, including lifestyle changes, aging populations, environmental influences, and genetic predispositions.  Gastric cancer remains one of the most prevalent cancers globally, with regions such as East Asia (especially Japan, China, and South Korea) and parts of Latin America and Europe witnessing high rates of incidence. Gastrointestinal (GI) cancers were more prevalent in men, accounting for 60.5% of cases, compared to 39.5% in women. The highest incidence of GI cancer was observed in India's northeastern region, with Aizawl district recording an Age-Adjusted Rate (AAR) of 126.9 per 100,000 among males, and Papumpare district showing an AAR of 75.9 per 100,000 among females. Although the incidence rate has slightly decreased in some developed countries due to improvements in screening and dietary habits, the overall global burden of gastric cancer is still substantial. According to various reports, gastric cancer ranks as one of the leading causes of cancer-related deaths worldwide. As more people are diagnosed with gastric cancer annually, the demand for effective therapies ranging from traditional chemotherapy to advanced targeted and immunotherapy has surged, directly contributing to the growth of the gastric cancer therapy market.

In addition to aging, lifestyle factors such as poor diet, smoking, alcohol consumption, and high levels of salt intake play a significant role in the rising incidence of gastric cancer. Alcohol consumption remains a major public health issue, contributing to over 3 million deaths annually. According to the World Health Organization (WHO), global per capita alcohol consumption in 2019 was 5.5 liters of pure alcohol per person aged 15 and older. Although there has been a modest decline in consumption since 2010, the majority of alcohol-related fatalities continue to occur among men. The global shift towards processed foods, rich in preservatives and lacking in essential nutrients, has contributed to the increased occurrence of gastric cancer, particularly in developed and urbanized areas. Countries in transition, with changing dietary patterns and more sedentary lifestyles, are also seeing a rise in gastric cancer cases. As these lifestyle-related factors continue to influence public health, the number of patients seeking treatment for gastric cancer increases, stimulating the growth of the therapy market. Advancements in diagnostic tools and screening methods, such as endoscopy, biomarker testing, and genetic profiling, have improved the detection of gastric cancer, even in its early stages. As detection becomes more efficient and accessible, more people are diagnosed at various stages of the disease, contributing to the overall rise in the incidence rate. This increase in early-stage diagnoses is encouraging more patients to seek medical intervention, thereby expanding the market for gastric cancer therapies. Early detection also allows for the use of newer therapies, such as immunotherapies and targeted treatments, which have shown promising results in improving survival rates and quality of life.

Aging Global Population

The aging global population is a critical driver of growth in the global gastric cancer therapy market. As populations in developed and developing countries continue to age, the prevalence of age-related diseases, including cancer, increases. The rate of population aging is accelerating rapidly. In 2020, the number of individuals aged 60 and above surpassed the number of children under 5 years old. Between 2015 and 2050, the proportion of the global population over the age of 60 is expected to nearly double, increasing from 12% to 22%. Gastric cancer is known to have a higher incidence in older populations. Age is a key risk factor for gastric cancer, with many cases diagnosed in individuals over the age of 50. Approximately 80% of stomach cancer cases are found in those aged between 60 and 80, while the development of stomach cancer before the age of 40 is uncommon. This demographic shift is driving both the volume of cases and the need for effective therapeutic interventions.

With age, the likelihood of developing various forms of cancer—including gastric cancer—increases. The aging process is linked to genetic mutations and a decline in the body’s ability to repair cellular damage, which can lead to tumor formation. Gastric cancer is often diagnosed at later stages in older patients, where the cancer is more advanced, necessitating complex treatment regimens. As the median age of populations continues to rise, the number of cancer cases, including gastric cancer, is expected to grow proportionally. This shift contributes directly to the expanding market for gastric cancer therapies as healthcare systems strive to provide treatment for this increasing number of older patients. One of the most significant contributors to the aging population is the increase in life expectancy globally. Advances in healthcare, better nutrition, improved living conditions, and public health initiatives have led to longer life spans. As people live longer, they are more likely to develop diseases associated with aging, such as cancer. Older adults are often affected by multiple chronic conditions, which can complicate the diagnosis, treatment, and management of gastric cancer. Co-morbidities such as cardiovascular disease, diabetes, and hypertension are common among the elderly, and these conditions can influence the treatment approach for gastric cancer. In many cases, older patients require personalized treatment regimens that take into account both the cancer and their existing health issues. As the number of elderly patients increases, there is a growing need for tailored therapies and medical interventions that can effectively manage gastric cancer in the context of other chronic conditions, thus driving the demand for specialized gastric cancer therapies.

Innovations in Therapeutic Approaches

Innovations in therapeutic approaches are driving significant transformations in the Global Gastric Cancer Therapy Market. These advancements are revolutionizing the treatment landscape for gastric cancer patients, offering more effective and tailored interventions. Immunotherapies, particularly immune checkpoint inhibitors, are gaining prominence. These therapies harness the immune system to target and attack cancer cells. Monoclonal antibodies that inhibit checkpoint proteins like PD-1 and CTLA-4 have shown remarkable success in extending survival and improving outcomes in advanced gastric cancer cases. Targeted therapies are being developed to specifically address molecular alterations driving gastric cancer growth. These therapies disrupt signaling pathways, such as HER2-targeted agents, aimed at tumors with HER2 overexpression. Similarly, VEGF inhibitors target blood vessel formation crucial for tumor growth. Precision medicine approaches utilize genetic profiling to guide treatment decisions. Identifying specific genetic mutations and alterations helps match patients with the most suitable therapies, minimizing adverse effects and maximizing therapeutic benefits. Combination therapies are emerging as a promising strategy. These regimens combine different treatment modalities like chemotherapy, targeted agents, and immunotherapies to enhance treatment efficacy and overcome resistance mechanisms. Furthermore, novel drug delivery systems, such as nanoparticles, improve the targeted delivery of therapeutic agents to cancer cells, minimizing damage to healthy tissue. As research continues, these innovative therapeutic approaches are reshaping the Gastric Cancer Therapy Market by offering patients more effective treatments, extending survival, and improving their quality of life.

Download Free Sample Report

Key Market Challenges

Limited Treatment Options for Advanced Stages

Limited treatment options for advanced stages of gastric cancer pose a significant challenge within the Global Gastric Cancer Therapy Market. Advanced gastric cancer often exhibits aggressive behavior and has typically spread to other parts of the body, reducing the efficacy of standard treatment approaches. Chemotherapy, targeted therapies, and immunotherapies are common treatments, but their effectiveness can diminish as cancer becomes resistant to these interventions. Resistance mechanisms can involve genetic mutations, altered signaling pathways, and immune evasion tactics employed by cancer cells. The complexity of late-stage gastric cancer necessitates the development of innovative therapies to address treatment resistance. Researchers are exploring combination therapies that target multiple pathways simultaneously to overcome resistance and improve treatment outcomes. Additionally, the discovery of new therapeutic targets and the development of novel agents hold promise for expanding treatment options. Clinical trials play a pivotal role in testing and validating these new approaches. By enrolling patients with advanced gastric cancer, these trials contribute to the identification of effective treatments and potentially lead to regulatory approvals for novel therapies. To enhance the treatment landscape for advanced gastric cancer, collaborative efforts among pharmaceutical companies, research institutions, regulatory agencies, and patient advocacy groups are crucial. By addressing the limited treatment options for advanced stages, the Gastric Cancer Therapy Market can improve patient survival rates and quality of life.

Lack of Biomarkers for Treatment Response

The lack of reliable biomarkers for treatment response is a significant challenge in the Global Gastric Cancer Therapy Market. Biomarkers are molecular or genetic indicators that provide insights into disease progression, treatment effectiveness, and potential side effects. In gastric cancer, the absence of well-established biomarkers hinders the ability to predict how individual patients will respond to specific therapies. This lack of predictive biomarkers leads to a "one-size-fits-all" approach to treatment, where patients receive standard therapies without the benefit of tailoring treatment to their unique characteristics. As a result, some patients may not respond optimally to treatments, while others might experience unnecessary side effects.

Researchers are actively investigating potential biomarkers that could guide treatment decisions in gastric cancer. These biomarkers may include genetic mutations, protein expression levels, or molecular signatures specific to the tumor. For example, the HER2 protein's overexpression serves as a biomarker for targeted therapies in certain cases of gastric cancer. The development and validation of reliable biomarkers are complex processes that require extensive clinical research and validation. Challenges include identifying biomarkers that accurately predict treatment response across diverse patient populations and standardizing testing methods to ensure consistency. The integration of precision medicine into the Gastric Cancer Therapy Market relies heavily on identifying biomarkers that indicate which therapies are most likely to succeed for individual patients. Collaborative efforts involving researchers, clinicians, regulatory agencies, and pharmaceutical companies are essential to advancing biomarker discovery, ultimately leading to more personalized and effective treatment strategies for patients with gastric cancer.

Key Market Trends

Immunotherapies Dominance

Immunotherapies' dominance in the Global Gastric Cancer Therapy Market stems from their revolutionary impact on cancer treatment paradigms. Immunotherapy harnesses the body's own immune system to recognize and eliminate cancer cells, offering a fundamentally different approach compared to traditional therapies. In gastric cancer, where treatment options have been limited, immunotherapies have emerged as a beacon of hope. Immune checkpoint inhibitors are a major subset of immunotherapies that have gained significant traction. These drugs target checkpoint proteins like PD-1, PD-L1, and CTLA-4, which cancer cells exploit to evade immune responses. By blocking these proteins, immune checkpoint inhibitors "release the brakes" on the immune system, allowing it to mount a potent attack against cancer cells.

This dominance in the Gastric Cancer Therapy Market is attributed to the remarkable success of immunotherapies in clinical trials. Some patients with advanced gastric cancer who had exhausted other treatment options have experienced prolonged survival and improved quality of life due to immunotherapy. Immunotherapies' efficacy extends beyond advanced cases. Their potential to stimulate long-lasting immune responses has raised interest in combining them with other treatments, such as targeted therapies and chemotherapy, to maximize effectiveness. However, not all patients respond equally to immunotherapies, and some might experience immune-related adverse events. Biomarker discovery is ongoing to identify those most likely to benefit. Collaborative efforts between researchers, pharmaceutical companies, and healthcare providers are essential to refining treatment strategies and expanding access to these transformative therapies. The dominance of immunotherapies signals a paradigm shift in gastric cancer treatment, underscoring the market's rapid evolution and the potential for significantly improved outcomes for patients who previously faced limited options.

Biomarker Development

Biomarker development is a critical aspect of the Global Gastric Cancer Therapy Market, revolutionizing treatment strategies by enabling personalized and targeted approaches. Biomarkers are molecular indicators that provide insights into disease characteristics, treatment responses, and prognosis. In the context of gastric cancer, biomarkers hold immense potential to guide treatment decisions and optimize patient outcomes. Researchers are actively identifying and validating biomarkers that correlate with different aspects of gastric cancer, such as its molecular subtypes, progression, and response to specific therapies. These biomarkers can include genetic mutations, protein expression patterns, and molecular signatures unique to each patient's tumor. Predictive biomarkers are particularly valuable as they help identify patients who are most likely to respond to certain treatments. For instance, HER2 overexpression is a biomarker that predicts response to HER2-targeted therapies in some gastric cancer cases. Prognostic biomarkers aid in estimating the likely course of the disease. Combining predictive and prognostic biomarkers assists in tailoring treatment plans for optimal outcomes. However, biomarker development faces challenges. Biomarkers need to be rigorously validated across diverse patient populations to ensure their accuracy and reliability. Standardizing testing methods and interpretation criteria are essential for consistent results across different laboratories and clinical settings. Advancements in technologies like next-generation sequencing and proteomics are accelerating biomarker discovery. Collaborations between research institutions, pharmaceutical companies, and regulatory bodies facilitate the integration of validated biomarkers into clinical practice, enabling oncologists to make informed treatment decisions. In summary, biomarker development is shaping the Gastric Cancer Therapy Market by guiding personalized treatment strategies and improving patient outcomes. As more biomarkers are discovered, validated, and incorporated into clinical practice, the market's evolution continues toward precision medicine, optimizing therapeutic approaches for gastric cancer patients.

Segmental Insights

Therapy Type Insights

Based on category of therapy type, Targeted Therapy segment has emerged as the fastest-growing category in the global gastric cancer therapy market due to its effectiveness, precision, and lower side-effect profile compared to traditional therapies such as chemotherapy and radiation. This shift towards targeted therapies is driven by several key factors that are reshaping the treatment landscape for gastric cancer. Targeted therapies are based on a deeper understanding of the genetic and molecular mechanisms underlying gastric cancer. Unlike traditional therapies that attack rapidly dividing cells indiscriminately, targeted therapies are designed to specifically target cancer cells by inhibiting the molecules and pathways that drive tumor growth. This approach aligns with the broader trend in medicine toward precision and personalized treatment, where therapies are tailored to the genetic profile of the patient and their cancer. As the medical community increasingly embraces precision medicine, the demand for targeted therapies has risen sharply, driving growth in this segment.

Targeted therapies have demonstrated significantly higher efficacy in clinical trials compared to traditional therapies, which often come with severe side effects. This advantage makes them more appealing to both healthcare providers and patients, as the therapies are not only more effective but also associated with fewer adverse reactions. For gastric cancer patients, whose quality of life is a major consideration, this is a compelling reason for the accelerated adoption of targeted therapies. The rise in molecular diagnostic techniques, such as next-generation sequencing (NGS), has allowed for better identification of specific genetic mutations and biomarkers associated with gastric cancer. These diagnostic tools enable the identification of patients who are most likely to benefit from targeted therapies, thus improving patient outcomes. As a result, more patients are being treated with targeted therapies, contributing to the rapid growth of this segment.

Download Free Sample Report

Regional Insights

Based on region, North American region has emerged as the largest market in the global gastric cancer therapy market due to a combination of factors that contribute to its dominance. These factors include advanced healthcare infrastructure, increasing prevalence of gastric cancer, significant investments in research and development, and a high rate of therapeutic innovation. Gastric cancer is a significant health concern in North America, with a rising incidence driven by lifestyle factors such as diet, smoking, and alcohol consumption. Although it is more common in Eastern countries, North America still reports a considerable number of cases, creating a robust demand for effective therapies.

North America boasts state-of-the-art healthcare facilities and highly skilled medical professionals, which contribute to high treatment success rates and patient outcomes. The region's advanced medical technology, coupled with a well-established healthcare system, allows for the efficient delivery of gastric cancer therapies, thus driving market growth. North America, particularly the United States, is home to a strong pharmaceutical and biotechnology sector, which plays a pivotal role in the development of innovative gastric cancer treatments. Substantial investments in research and development (R&D) by key players in the market, including pharmaceutical giants and research institutions, have resulted in the continuous development of new therapies, such as targeted therapies, immunotherapies, and personalized treatments. This focus on R&D enhances the availability of cutting-edge treatment options, further strengthening the market.

Recent Development

• In February 2025, Signet Therapeutics, a clinical-stage biotechnology company, has announced that its investigational treatment, SIGX1094, has received FDA Fast Track designation for diffuse gastric cancer.
• In October 2024, The European Commission's approval is in line with the most recent ESMO Gastric Cancer Living Guidelines, which now endorse zolbetuximab in combination with chemotherapy as a first-line treatment for patients with CLDN18 expression.
• In August 2024, CARsgen has successfully completed patient enrollment in its pivotal Phase 2 clinical trial (NCT04581473) assessing satricabtagene autoleucel (satri-cel; CT041), an investigational CAR-T therapy targeting CLDN18.2, for the treatment of CLDN18.2-positive advanced gastric and gastroesophageal junction (GC/GEJ) cancer.
• In August 2024, AstraZeneca and Daiichi Sankyo have announced that their antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), has received conditional approval from the China National Medical Products Administration (NMPA) for the treatment of gastric cancer. Enhertu is now approved for use as a monotherapy in adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have previously received at least two prior lines of treatment.

Key Market Players

• Abbott Laboratories Inc.
• Amgen, Inc.
• Celltrion Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Agilent Technologies Inc.
• AstraZeneca Plc
• Pfizer Inc.
• Eli Lilly & Co.
• GlaxoSmithKline Plc.

Report Scope:

In this report, the Global Gastric Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Gastric Cancer Therapy Market, By Therapy Type:

o   Chemotherapy

o   Targeted Therapy

o   Immunotherapy

o   Radiation Therapy

o   Surgery

• Gastric Cancer Therapy Market, By End User:

o   Ambulatory Surgery Centers

o   Hospitals and Specialty Clinics

o   Other

• Gastric Cancer Therapy Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastric Cancer Therapy Market.

Available Customizations:

Global Gastric Cancer Therapy Market report with the given Market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional Market players (up to five).

Global Gastric Cancer Therapy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com